

Enhance Patient Care with Whole Genome Genetic Testing

Gain new, clinically relevant insights into your patients' disease risk and medication response with the MyOme Proactive Health reports.





The MyOme® Proactive Health Single-Gene Risk™ report analyzes a curated list of genes associated with actionable, adult-onset, single-gene conditions, including inherited cardiovascular diseases and cancers. Insights from the report can help you drive better patient outcomes.

MyOme Single-Gene Report Benefits



Reduce risks with proactive screening



Identify at-risk patients before symptoms present



Make informed preventive care strategies and lifestyle changes



Who Can Benefit From This Test?

This Single-Gene Risk™ screening test is intended for adults who:

- Want to learn about genetic risks for actionable conditions for which they have no known family or personal history
- Are not seeking a diagnosis for a condition covered by this test based on family or personal history



This Test May Not Benefit All Patients

Patients with a personal, family or other factor suggestive of a condition in the Single-Gene report may require further screening or diagnostic genetic testing. MyOme provides patients with access to genetic counseling to help ensure comprehensive risk assessment and management.

Important Considerations: The Single-Gene Risk™ report is intended as a screening tool and may not cover all potential genes or detect all variants associated with certain conditions. A patient may still be at risk of developing a condition if the Baseline Risk report result is negative.





Incorporate your patient's genetic factors into their medication plan with the MyOme Proactive Health Medication Response™ pharmacogenomic test. Our test analyzes pharmacogenes that affect the metabolism of a wide range of medications, influencing a drug's effectiveness and risk of side effects.

Integrating the Medication Response report with your patient's medical history, professional guidelines^{1,2}, and FDA guidance³ enables drug selection and dosing decisions for safer, more effective treatments.

MyOme Medication Response Report Benefits



Minimize adverse reactions



Ensure medication efficacy



Identify optimal medications faster



Reduce the need for frequent adjustments

Important Considerations: Medication response can be influenced by your patient's other medications, health, age, weight, and diet. While the Medication Response report analyzes key genes and variants, other untested genes or variants may also affect drug response. Interpret results within the full context of the patient's medical profile. Our test targets gene variants with established guidelines, but not all medications may be affected, as genetic influences on many drugs remain incompletely understood.



Support at Every Step

We are committed to helping providers communicate complex topics by providing videos, materials, and other resources to enhance the patient experience.



Make MyOme Proactive Health part of your patient care. Contact support@myome.com to set up an account.

The test described above was developed, and its performance characteristics were determined by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). College of American Pathologists (CAP) accredited and CLIA certified

- 1. https://cpicpgx.org/guidelines/
- 2. https://www.pharmgkb.org/guidelineAnnotations
- $3.\ https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations$